S-OA-D Oral Abstracts - Session D - Allogeneic Transplants

Track: BMT Tandem "Scientific" Meeting
Thursday, February 12, 2015: 4:45 PM-6:45 PM
Seaport Ballroom ABC (Manchester Grand Hyatt)
Chairs:
Steven M. Devine, MD and Jerome Ritz, MD

Disclosures:
S. M. Devine, Nothing To Disclose

J. Ritz, Biothera, Clinical Advisory Board member: Advisory Board
Kiadis Pharma, Clinical Advisory Board member: Advisory Board

22
A Survival Benefit for Reduced Intensity Allogeneic Transplants from Young Unrelated Donors Compared to Older Sibling Donors Depends on the Graft CD8 T-Cell Content
Ran Reshef, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania; Austin P. Huffman, BA, Perelman School of Medicine at the University of Pennsylvania; Amy Gao, MS, Perelman School of Medicine at the University of Pennsylvania; Mary Sell, BS MT, Perelman School of Medicine at the University of Pennsylvania; Marlise R. Luskin, MD, Perelman School of Medicine at the University of Pennsylvania; Selina Luger, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania; Alison Loren, MD, MS, Perelman School of Medicine at the University of Pennsylvania; Elizabeth O. Hexner, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania; Sunita D. Nasta, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania; Noelle V. Frey, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania; Saar Gill, MBBS, PhD, Perelman School of Medicine at the University of Pennsylvania; James Mangan, MD PhD, Perelman School of Medicine at the University of Pennsylvania; Lee P Richman, BA, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; Taku Kambayashi, MD PhD, Perelman School of Medicine at the University of Pennsylvania; Edward A. Stadtmauer, MD, Perelman School of Medicine at the University of Pennsylvania; Robert H Vonderheide, MD DPhil, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania; Rosemarie Mick, MS, Perelman School of Medicine at the University of Pennsylvania; David L. Porter, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania

23
Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical Peripheral Blood CD34+ Cells (HaploCD34+) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection, and Frequent Pre-Engraftment Syndrome
Matias E Sanchez, MD, Memorial Sloan Kettering Cancer Center; Doris M. Ponce, MD, Memorial Sloan Kettering Cancer Center; Emily Lauer, BS, Memorial Sloan Kettering Cancer Center; Marissa Lubin, BA, Memorial Sloan Kettering Cancer Center; Jonathan Barone, BS, American Red Cross; Courtney Byam, BS, Memorial Sloan Kettering Cancer Center; Parastoo Dahi, MD, Memorial Sloan Kettering Cancer Center; Richard Meagher, PhD, Memorial Sloan-Kettering Cancer Center; Hugo Castro-Malaspina, M.D., Memorial Sloan Kettering Cancer Center; Ann A. Jakubowski, PhD, MD, Memorial Sloan Kettering Cancer Center; Guenther Koehne, MD, PhD, Memorial Sloan-Kettering Cancer Center; Esperanza Papadopoulos, MD, Memorial Sloan Kettering Cancer Center; Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center; Craig Sauter, MD, Memorial Sloan Kettering Cancer Center; Roni Tamari, Memorial Sloan Kettering Cancer Center; James W Young, MD, FACP, Memorial Sloan Kettering Cancer Center; Andromachi Scaradavou, MD, Memorial Sloan Kettering Cancer Center; Nancy A Kernan, MD, Memorial Sloan Kettering Cancer Center; Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center; Richard J. O'Reilly, MD, Memorial Sloan Kettering Cancer Center; Juliet Barker, MBBS (Hons) FRACP, Memorial Sloan Kettering Cancer Center

24
Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease (SCD)
Santosh Saraf, MD, University of Illinois at Chicago; Annie Oh, MD, University of Illinois at Chicago; Dolores Mahmud, PhD, University of Illinois at Chicago; Karen Sweiss, PharmD, BCOP, University of Illinois at Chicago; Pritesh Patel, MB, ChB, University of Illinois at Chicago; Matthew Koshy, MD, University of Illinois at Chicago; Sally Campbell-Lee, MD, University of Illinois at Chicago; Nadim Mahmud, MD, PhD, University of Illinois at Chicago; Victor Gordeuk, MD, University of Illinois at Chicago; Damiano Rondelli, MD, University of Illinois at Chicago

25
Allogeneic Haematopoietic Stem Cell Transplantation for Systemic Onset Juvenile Idiopathic Arthiritis
Juliana Silva, MD, Great Ormond Street Hospital for Children NHS Trust; Julie Glanville, Great Ormond Street Hospital for Children NHS Trust; Fani Ladomenou, Great North Children's Hospital; Rachael Hough, University College Hospital London; Ben Carpenter, University College Hospital London; Vicky Grandage, University College Hospital London; Kanchan Rao, MD, MRCPCH, Great Ormond Street Hospital for Children NHS Trust; Persis Amrolia, MD, PhD, Great Ormond Street Hospital for Children NHS Trust; Robert Chiesa, MD, PhD, Great Ormond Street Hospital for Children; Paul Brogan, Great Ormond Street Hospital; Mark Friswell, Great North Children's Hospital; Andrew J Cant, MD, Great North Children's Hospital; Zohreh Nademi, Dr, Great North Children's Hospital; Mary Slatter, MD, Great North Children's Hospital; Mario Abinun, Great North Children's Hospital; Paul Veys, MBBS, Great Ormond Street Hospital for Children

26
Induction of Durable Mixed Hematopoietic Chimerism and Immune Tolerance in Monkeys
Paula Alonso Guallart, D.V.M., Columbia University; Jonah Zitsman, Columbia University; Hugo Sondermeijer, M.D. M.S., Columbia University; David Woodland, M.D., Columbia University; Yojiro Kato, M.D., Columbia University; Joshua Weiner, M.D., Columbia University; Adam Griesemer, M.D., Columbia University; Leo Bühler, M.D., Massachusetts General Hospital; Alicia McMurchy, Ph.D., The University of British Columbia; Megan Levings, Ph.D., The University of British Columbia | Child and Family Research Institute; Megan Sykes, MD, Columbia University; Raimon Duran-Struuck, D.V.M. Ph.D. DACLAM, Columbia University

27
Health-Related Quality of Life Among Older Adult Related Hematopoietic Stem Cells (HSC) Donors (>60 yrs.) Is Equivalent to or Better Than That of Younger Adult Related Donors (18-60 yrs.)
Galen E. Switzer, PhD, University of Pittsburgh; Jessica G. Bruce, BA, University of Pittsburgh; Deidre M. Kiefer, M.P.H., Center for International Blood and Marrow Transplant Research, National Marrow Donor Program; Hati Kobusingye, MS, National Marrow Donor Program; Rebecca J. Drexler, BS, AAS, National Marrow Donor Program; RaeAnne M. Besser, BS, National Marrow Donor Program; Roberta J. King, MPH, CIBMTR/National Marrow Donor Program; Mary M. Horowitz, MD, MS, CIBMTR and Medical College of Wisconsin; Dennis L. Confer, MD, National Marrow Donor Program; Michael A. Pulsipher, MD, University of Utah School of Medicine

28
Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Philip A Thompson, MBBS, FRACP, FRCPA, The University of Texas MD Anderson Cancer Center; Travis Perera, MBChB, FRACP, FRCPA, Royal Melbourne Hospital; David Marin, The University of Texas MD Anderson Cancer Center; Betul Oran, MD, The University of Texas MD Anderson Cancer Center; Uday R. Popat, MD, UT MD Anderson Cancer Center; Muzaffar H. Qazilbash, MD, The University of Texas MD Anderson Cancer Center; Nina Shah, MD, The University of Texas MD Anderson Cancer Center; Simrit Parmar, MD, The University of Texas MD Anderson Cancer Center; Katy Rezvani, MD, The University of Texas MD Anderson Cancer Center; Amanda Olson, M.D., The University of Texas MD Anderson Cancer Center; Partow Kebriaei, MD, The University of Texas MD Anderson Cancer Center; Gabriela Rondon, MD, The University of Texas MD Anderson Cancer Center; Amin Alousi, MD, UT MD Anderson Cancer Center; Stefan O. Ciurea, MD, The University of Texas MD Anderson Cancer Center; Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center; Ashish Bajel, MBBS, Royal Melbourne Hospital; Jeffrey Szer, MB, BS, FRACP, Royal Melbourne Hospital; Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center; David Stuart Ritchie, MBChB FRACP FRCPA PhD, Royal Melbourne Hospital; Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center

29
Acceleration of Umbilical Cord Blood (UCB) Stem Engraftment: Results of a Phase I Clinical Trial with Stemregenin-1 (SR1) Expansion Culture
John E. Wagner, MD, University of Minnesota; Claudio G. Brunstein, MD, PhD, University of Minnesota Medical Center; David McKenna, MD, University of Minnesota; Darin Sumstad, University of Minnesota Medical Center, Fairview; Suzanne Maahs, PharmD, Novartis Institutes for BioMedical Research; Mary J. Laughlin, MD, Global Program Medical Director Stem Cell Therapy Integrative Hospital Care Franchise, Novartis Pharmaceuticals Corp; Michael S. Perry, DVM, PhD, FRCVS, Novartis Pharmaceuticals Corporation; Anthony E. Boitano, PhD, Genomics Inst. of the Novartis Research Foundation; Michael Cooke, PhD, Genomics Inst. of the Novartis Research Foundation; Conrad C. Bleul, MD, Novartis Institutes for Biomedical Research, Translational Medicine ATI